OBI — Ondine Biomedical Balance Sheet
0.000.00%
Last trade - 00:00- £81.38m
- £75.95m
- CA$2.65m
Annual balance sheet for Ondine Biomedical, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 30.4 | 13.1 | 2.98 | 9.77 | 10.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.248 | 0.182 | 0.326 | 0.513 | 0.46 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 33.5 | 15.1 | 4.75 | 12.2 | 13.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.601 | 1.4 | 0.949 | 0.597 | 1.06 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 34.1 | 16.6 | 5.73 | 12.8 | 14.4 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.92 | 3.91 | 3.49 | 5.95 | 10.8 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Liabilities | 4.48 | 4.92 | 3.65 | 5.95 | 10.9 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 29.7 | 11.6 | 2.08 | 6.88 | 3.48 |
| Total Liabilities & Shareholders' Equity | 34.1 | 16.6 | 5.73 | 12.8 | 14.4 |
| Total Common Shares Outstanding |